CD38 and Miyoshi myopathy: Furthermore, daratumumab, a CD38 monoclonal antibody, can induce cellular death in MM cells through complement-dependent cytotoxicity, antibody-dependent cytotoxicity, antibody-dependent cellular phagocytosis with an expansion of clonal effector T cells, and decrease of regulatory T cells and, therefore, could eliminate emergent resistant subclones [37].